Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 13/20 | 0.60 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18010234 | 0.88 | ADORA2B (0.47) | ADORA2BACACBACACALMNAALDH1A1 | |
| SCHEMBL18010239 | 0.87 | ADORA2B (0.46) | ADORA2BACACBACACALMNAALDH1A1 | |
| SCHEMBL18010229 | 0.87 | ADORA2B (0.46) | ADORA2BACACBACACALMNAALDH1A1 | |
| SCHEMBL7030156 | 0.87 | ACACB (0.58) | ADORA2BACACBACACALMNAMEN1 | |
| SCHEMBL16643780 | 0.86 | ADORA2B (0.53) | ADORA2BACACBACACALMNAALDH1A1 | |
| SCHEMBL5132221 | 0.84 | ALDH1A1 (0.40) | ADORA2BLMNAALDH1A1MEN1POLB | |
| SCHEMBL2777200 | 0.81 | ADORA2B (0.60) | ADORA2BACACBACACAALDH1A1HPGD | |
| SCHEMBL5130407 | 0.81 | ALDH1A1 (0.41) | ADORA2BACACBACACALMNAALDH1A1 | |
| SCHEMBL18010254 | 0.81 | ALDH1A1 (0.41) | ADORA2BACACBACACALMNAALDH1A1 | |
| SCHEMBL16637629 | 0.79 | ACACB (0.52) | ADORA2BACACBACACALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | ADORA2A, ADORA2B, ADORA3 | ADORA2B 2/4885ACACB 1136/4885ACACA 2572/4885 |
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | ADORA2A, ADORA2B, ADORA3 | ADORA2B 2/4885ACACB 1136/4885ACACA 2572/4885 |
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | ADORA2B 487/4885ACACB 1062/4885ACACA 996/4885 |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | ADORA2B 487/4885ACACB 1062/4885ACACA 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.